Agios Pharmaceuticals (AGIO) Valuation Check After Extended Share Price Weakness

Simply Wall St.02-06

AdvertisementWhat recent performance says about Agios Pharmaceuticals (AGIO) Agios Pharmaceuticals (AGIO) has drawn attention after recent share performance, with the stock down about 4% over the past...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2609569769?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-02-06 14:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609569769","market":"hk","top_or_hot":-1,"title":"Agios Pharmaceuticals (AGIO) Valuation Check After Extended Share Price Weakness","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhat recent performance says about Agios Pharmaceuticals (AGIO) Agios Pharmaceuticals (AGIO) has drawn attention after recent share performance, with the stock down about 4% over the past...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-valuation-check-after-extended-sh\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agios Pharmaceuticals (AGIO) Valuation Check After Extended Share Price Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgios Pharmaceuticals (AGIO) Valuation Check After Extended Share Price Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-06 14:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-valuation-check-after-extended-sh><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhat recent performance says about Agios Pharmaceuticals (AGIO) Agios Pharmaceuticals (AGIO) has drawn attention after recent share performance, with the stock down about 4% over the past...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-valuation-check-after-extended-sh\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-valuation-check-after-extended-sh","article_id":"2609569769","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-valuation-check-after-extended-sh","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2609569769","pubTimestamp":1770358198,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"What recent performance says about Agios Pharmaceuticals (AGIO)\nAgios Pharmaceuticals (AGIO) has drawn attention after recent share performance, with the stock down about 4% over the past week, roughly 3% over the past month, and 35% over the past 3 months.\nSee our latest analysis for Agios Pharmaceuticals.\nStepping back, Agios Pharmaceuticals' recent weakness adds to a tougher stretch, with a 90 day share price return of a 34.7% decline and a 1 year total shareholder return of a 22.8% loss,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AGIO":"Agios Pharmaceuticals, Inc."},"translate_title":"Agios Pharmaceuticals(AGIO)股价长期疲软后进行估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGIO":1.5},"content_text":"AdvertisementWhat recent performance says about Agios Pharmaceuticals (AGIO) Agios Pharmaceuticals (AGIO) has drawn attention after recent share performance, with the stock down about 4% over the past week, roughly 3% over the past month, and 35% over the past 3 months. See our latest analysis for Agios Pharmaceuticals. Stepping back, Agios Pharmaceuticals' recent weakness adds to a tougher stretch, with a 90 day share price return of a 34.7% decline and a 1 year total shareholder return of a 22.8% loss, which suggests momentum has been fading rather than building. If this volatility has you looking beyond a single biotech name, it could be a good time to scan a wider group of healthcare focused AI opportunities through our list of 25 healthcare AI stocks. So with Agios trading at a discount to analyst targets and some improvement in annual revenue and net income trends, is the current price underestimating the pipeline potential, or is the market already factoring in the anticipated growth story? Most Popular Narrative: 27.7% Undervalued Agios Pharmaceuticals' most followed narrative pegs fair value at $36.75 per share versus the last close of $26.57, framing a wide gap that rests heavily on how its pipeline converts into future cash flows.  Upcoming potential FDA approval and commercial launch of PYRUKYND for thalassemia in the U.S. is set to significantly expand Agios' addressable market, driven by the high rate of disease diagnosis through newborn screening and well-defined patient populations, which should lift revenue growth in coming years.  Read the complete narrative. Curious what kind of revenue ramp, margin shift, and future earnings multiple are baked into that fair value? The full narrative spells out the growth curve and the valuation math behind it in detail, including how analysts weigh rapid top line expansion against ongoing losses. Result: Fair Value of $36.75 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, that upside view still leans heavily on PYRUKYND delivering across new indications, while high R&D and SG&A spending keeps profitability out of near reach. Find out about the key risks to this Agios Pharmaceuticals narrative. Another Way To Look At Valuation The narrative leans on future cash flows, but the current P/S of 34.6x tells a very different story. That multiple is far above the US Biotechs average of 11.5x and the fair ratio of 0x. This points to meaningful valuation risk if expectations reset. Which signal do you trust more? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:AGIO P/S Ratio as at Feb 2026 Build Your Own Agios Pharmaceuticals Narrative If you see the numbers differently or want to stress test your own assumptions, you can pull up the same data and build a custom view in just a few minutes, then Do it your way. A great starting point for your Agios Pharmaceuticals research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision. Looking for more investment ideas? If you stop with one stock, you miss the bigger picture. Use the screener to quickly surface fresh ideas that match what you care about most.  Target potential mispricings by scanning our list of 55 high quality undervalued stocks that might not yet be on everyone’s radar. Prioritise resilience first by filtering for companies in the solid balance sheet and fundamentals stocks screener (46 results) so you can focus on businesses with sturdier financial footing. Get ahead of the crowd by reviewing a screener containing 25 high quality undiscovered gems that could add something different to your portfolio before attention builds.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609569769","isCrawlerRequest":true}